Powder: -20°C for 3 years | In solvent: -80°C for 1 year
AT-007 is an orally active CNS penetrant Aldose Reductase inhibitor for the treatment of Galactosemia (IC50: 100 pM). It reduces toxic galactitol levels and prevents disease complications in GALT deficiency rats.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 73.00 | |
5 mg | In stock | $ 158.00 | |
10 mg | In stock | $ 249.00 | |
25 mg | In stock | $ 463.00 | |
50 mg | In stock | $ 683.00 | |
100 mg | In stock | $ 973.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 173.00 |
Description | AT-007 is an orally active CNS penetrant Aldose Reductase inhibitor for the treatment of Galactosemia (IC50: 100 pM). It reduces toxic galactitol levels and prevents disease complications in GALT deficiency rats. |
Targets&IC50 | Aldose reductase:100 pM |
In vivo | AT-007 markedly reduces galactitol levels across all target tissues (liver, brain, and plasma) in GALT null rats, without elevating galactose or Gal-1P concentrations [2]. |
Molecular Weight | 425.4 |
Formula | C17H10F3N3O3S2 |
CAS No. | 2170729-29-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 35.71 mg/mL (83.94 mM), Sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
AT-007 2170729-29-8 Endocrinology/Hormones Metabolism Reductase inhibit Aldose Reductase Inhibitor AT 007 AT007 inhibitor